What condition can be developed due to the side effects of second generation antipsychotics (SGAs)?

Second-generation antipsychotics (SGAs) can have several side effects, one of which is the potential development of metabolic syndrome, which often includes significant weight gain, dyslipidemia, and insulin resistance leading to the risk of developing diabetes mellitus. Specifically, second-generation antipsychotics can lead to glucose dysregulation and ultimately increase the risk of Type 2 diabetes, which is often more associated with these medications.

Parkinsonism is a side effect related to the dopamine antagonism of antipsychotics, but it is usually more prevalent with first-generation antipsychotics. Type I diabetes and obsessive-compulsive disorder are not typically linked to the use of SGAs. Ketoacidosis, while a serious condition, is generally associated with uncontrolled diabetes rather than being a direct side effect of SGAs.

Thus, while metabolic complications can arise from SGAs, the risk of diabetes mellitus, particularly Type 2, is the condition most closely related to their use.